Stock Ratings / Health Care / LEXX / options

SNGX (44) MTVA (47) TCRT (31) KPRX (32) ⌘ Pro Terminal →

Lexaria Bioscience Corp. (LEXX) Options Positioning, Max Pain & Unusual Sweeps

$3.77 +14.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Lexaria Bioscience Corp. (LEXX) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $7.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LEXX)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (LEXX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for LEXX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LEXX)

✓Walkthrough of LEXX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LEXX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -61.88%📐 HORIZONTAL RANGE

2026-10-30O $3.63H $3.77L $3.09C $3.77VOL 37.7K

RES: $15.94SUP: $1.34SMA50: $5.27SMA200: $8.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LEXX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LEXX Butterfly Map → + Track LEXX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +52.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LEXX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LEXX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LEXX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LEXX)

Health Care Rank #427 of 1016 ⚔️ SNGX vs LEXX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LEXX vs. SNGX, MTVA, TCRT, KPRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lexaria Bioscience Corp. (LEXX) ranks #427 by composite RQD confidence (47/100, grade D) and #912 by equity capitalization ($7.9M). Within this direct 5-issuer industry benchmark cohort, LEXX leads on earnings valuation at N/A trailing P/E, while LEXX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. LEXX currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LEXX ACTIVE Lexaria Bioscience Corp.	D	47/100	—	96.0%	-35.0%	+14.24%	$7.9M	Benchmark Subject
SNGX Soligenix Inc.	D	44/100	—	—	-35.0%	-1.55%	$8.0M	/sngx-vs-lexx →
MTVA MetaVia Inc.	D	47/100	—	—	-35.0%	+4.39%	$7.8M	/mtva-vs-lexx →
TCRT Alaunos Therapeutics Inc.	E	31/100	—	—	-35.0%	-11.27%	$7.8M	/tcrt-vs-lexx →
KPRX Kiora Pharmaceuticals Inc.	E	32/100	—	—	-35.0%	-25.42%	$7.8M	/kprx-vs-lexx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-08-31 • CIK 0001348362

In its most recent audited fiscal period (FY2025, filed 2025-08-31), Lexaria Bioscience Corp. (LEXX) reported GAAP revenue of $705.9K (+52.0% vs. FY2024 revenue of $464.3K , and +212.1% cumulative change since FY2023) , GAAP net income of -$11.9M, operating cash flow of -$10.5M, and free cash flow of -$10.5M (-109.4% YoY). On the balance sheet, LEXX closed FY2025 with $6.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-08-31	$705.9K	-$11.9M	-$10.5M	-$10.5M	$6.1M	—
FY2024 (FY)	2024-08-31	$464.3K	-$5.8M	-$5.0M	-$5.0M	$9.8M	—
FY2023 (FY)	2023-08-31	$226.2K	-$6.7M	-$5.9M	-$5.9M	—	—

3. LEXX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LEXX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lexaria Bioscience Corp. (NASDAQ: LEXX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $3.77 (+14.24% 1D, market cap $7.9M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LEXX ranks #427 in composite RQD confidence.

How does LEXX compare to SNGX and MTVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LEXX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SNGX (Soligenix Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $8.0M) and MTVA (MetaVia Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, LEXX leads on earnings multiple (N/A) while LEXX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LEXX?

Per LEXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-08-31, CIK 0001348362), Lexaria Bioscience Corp. generated $705.9K in revenue (+52.0% YoY), -$11.9M in net income, and -$10.5M in free cash flow against $6.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LEXX trading relative to its 50-day, 200-day, and 52-week technical levels?

LEXX last traded at $3.77 (+14.24% on volume of 39,310 shares), positioning the stock -28.46% below its 50-day simple moving average ($5.27) and -57.92% below its 200-day simple moving average ($8.96). Across its 52-week range of $2.43 to $21.60, LEXX sits at the 7.0% percentile with a 14-day RSI of 48.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.30 to $4.24).

LEXX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is LEXX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for LEXX.

Direct Sub-Reports: LEXX RQD Cockpit LEXX 12M Forecast LEXX Earnings & Move LEXX Dividends & DRIP LEXX Insiders & 13F LEXX Whale Options LEXX Profit Sankey LEXX News & Why